| Literature DB >> 25897397 |
Lais Helena Camacho Navarro1, Joshua A Bloomstone2, Jose Otavio Costa Auler3, Maxime Cannesson4, Giorgio Della Rocca5, Tong J Gan6, Michael Kinsky7, Sheldon Magder8, Timothy E Miller6, Monty Mythen9, Azriel Perel10, Daniel A Reuter11, Michael R Pinsky12, George C Kramer7.
Abstract
BACKGROUND: Perioperative fluid therapy remains a highly debated topic. Its purpose is to maintain or restore effective circulating blood volume during the immediate perioperative period. Maintaining effective circulating blood volume and pressure are key components of assuring adequate organ perfusion while avoiding the risks associated with either organ hypo- or hyperperfusion. Relative to perioperative fluid therapy, three inescapable conclusions exist: overhydration is bad, underhydration is bad, and what we assume about the fluid status of our patients may be incorrect. There is wide variability of practice, both between individuals and institutions. The aims of this paper are to clearly define the risks and benefits of fluid choices within the perioperative space, to describe current evidence-based methodologies for their administration, and ultimately to reduce the variability with which perioperative fluids are administered.Entities:
Keywords: Fluid responsiveness; Fluid resuscitation; Goal-directed fluid therapy; Perioperative fluids
Year: 2015 PMID: 25897397 PMCID: PMC4403901 DOI: 10.1186/s13741-015-0014-z
Source DB: PubMed Journal: Perioper Med (Lond) ISSN: 2047-0525
Figure 1Perspective of the anesthesiologist’s tools (fluid and drugs) and the physiologic targets of these tools (blood volume, the heart, and blood vessels). The heart has two components (contractility and rate), and the blood vessels have two major characteristics (compliance and resistance). It is blood volume, heart, and blood vessels that produce pressure, flow, and oxygen delivery, while the intermediate physiologic functions and their metrics provide a means of assessing the cardiovascular state and how effective fluids are likely to be.
Trials of goal-directed therapy [23,29-59]
|
|
| ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| Elective cardiac surgery | ΔSV < 10% (esophageal Doppler) | Bolus 200 ml colloid | Standard of care | Less | More | Reduction of gut mucosal hypoperfusion, less postoperative complications, shorter ICU stay, shorter HLOS | Mythen and Webb [ |
| ΔCVP < 3 mmHg | |||||||
| Proximal femoral fracture repair | FTc > 400 ms, ΔSV < 10% (esophageal Doppler) | Bolus 3 ml/kg colloid | Standard of care | Similar | More | Shorter HLOS | Sinclair |
| Transthoracic esophagectomy | CVP < 5 mmHg | Restrictive regimen | Standard of care | No data | No data | Less postoperative pulmonary complications | Kita |
| Major bowel surgery | FTc > 350 ms | Bolus 3 ml/kg colloid | Standard of care | No data | More | Less critical care admission | Conway |
| ΔSV < 10% (Doppler) | |||||||
| Major elective surgery | FTc > 350 ms | Bolus 200 ml colloid | Standard of care (HR, CVP, MAP, UO) | Similar | More | Less PONV, earlier oral solid intake, shorter HLOS | Gan |
| ΔSV < 10% (Doppler) | |||||||
| Proximal femoral fracture repair | Doppler - FTc > 400 ms, | Bolus 200 ml colloid | Standard of care (without CVP or Doppler) | Similar | More | Less intraoperative hypotension, sooner medically fit for discharge | Venn |
| ΔSV < 10% | |||||||
| CVP - ΔCVP < 5 mmHg | |||||||
| Elective colorectal resection | Maintaining preoperative body weight | Restrictive regimen | Standard of care | Less | Similar | Less postoperative complications (tissue healing, cardiopulmonary) | Brandstrup |
| High-risk surgical patients (≥60 years old) | DO2 = 550 to 600 ml/min/m2 | Fluids, inotropes, vasodilators, vasopressors, RBC | Standard of care (without PAC) | No data | No data | More pulmonary embolism | Sandham |
| CI = 3.5 to 4.5 l/min/m2 | |||||||
| MAP = 70 mmHg | |||||||
| HR < 120 bpm, Ht ≥ 27% | |||||||
| Colorectal resection | ΔSV < 10% (Doppler) | Bolus 250 ml colloid | Routine monitoring (CVP = 12 to 15 mmHg) | Similar | More | Shorter recovery of gut function, less morbidity, shorter HLOS | Wakeling |
| ΔCVP < 3 mmHg | |||||||
| Elective colorectal resection | FTc > 350 ms | 7 ml/kg first bolus colloid, then bolus 3 ml/kg colloid | Standard of care (without bolus) | Similar | Similar | Less inotrope use, earlier diet, less days to medically fit, shorter HLOS | Noblett |
| ΔSV < 10% (Doppler) | |||||||
| Low-risk patients off-pump coronary surgery | PAC | No data | Standard of care (CVP) | No data | No data | More use of inotropes | Resano |
| Major abdominal surgery | O2ER < 27% | Colloid bolus, RBC, dobutamine | Standard of care (MAP, UO) | No data | No data | Less organ failure, shorter HLOS | Donati |
| Cardiac bypass surgery | GEDVI = 640 ml/m2 | Bolus 500 ml, vasopressors | Standard of care (CVP, MAP, clinical evaluation) | Similar | More | Shorter and reduced need for vasopressors, mechanical ventilation, and ICU therapy | Goepfert |
| CI > 2.5 l/min/m2 | |||||||
| MAP = 70 mmHg | |||||||
| High-risk surgery | ΔPP < 10% | Bolus colloid | Standard of care | Similar | More | Less postoperative complications, shorter time of mechanical ventilation, ICU stay and HLOS | Lopes |
| Moderate to high-risk cardiac surgery | DO2 = 450 to 600 ml/min/m2 | Bolus 100 ml colloid | CVP = 6 to 8 mmHg | Similar | More | Lower number of adjustments of inotropic agents | Kapoor |
| CI = 2.5 to 4.2 l/min/m2 | MAP = 90 to 105 mmHg | ||||||
| SVI = 30 to 65 ml/beat/m2 | UO > 1 ml/kg/h | ||||||
| ScvO2 > 70%, SVV < 10% | |||||||
| Off-pump coronary surgery | ITBVI > 850 ml/m2 | Bolus 500 ml colloid | Standard of care (MAP, CVP, HR) | Similar | More | Shorter HLOS | Smetkin |
| ScvO2 > 60% | |||||||
| Laparoscopic segmental colectomy | 2 GDT groups: | Bolus 200 ml colloid or 300 ml crystalloid | Standard of care | More (GDT crystalloid) | More (GDT colloid) | More postoperative complications on group GDT colloid | Senagore |
| ΔSV < 10% | |||||||
| Crystalloids | |||||||
| Major abdominal surgery | PVI < 13% | Bolus 250 ml colloid (norepinephrine to MAP > 65 mmHg) | Standard of care (MAP, CVP) | Less | Similar | Lower lactate levels | Forget |
| Elective surgery for GI malignancy | Serum lactate < 1.6 mmol/l | Bolus 250 to 1,000 ml colloid (depending serum lactate) | Restrictive regimen | Similar | Similar | Less systemic complications in patients that need postoperative supplementary fluids | Wenkui |
| Major abdominal surgery | Peak aortic flow velocity < 13% (Doppler) | Bolus 250 ml, vasopressors, dobutamine, restrictive crystalloids | Standard of care (12 ml/kg/h crystalloids) | Less (patients with complication) | More (patients with complication) | More postoperative complications | Futier |
| Peripheral artery bypass grafting | CI > 2.5 l/min/m | Bolus 250 ml colloid, dobutamine | Standard of care (MAP, CVP) | No data | Similar | No difference between groups | Van der Linden |
| Major abdominal surgery | CI > 2.5 l/min/m2 | Bolus 500 ml crystalloid, bolus 250 ml colloid, dobutamine, norepinephrine | Standard of care (MAP, CVP, UO) | Less | More | Less postoperative complications, shorter HLOS | Mayer |
| SVI > 35 ml/beat/m2 | |||||||
| MAP > 65 mmHg | |||||||
| Elective intra-abdominal surgery in high-risk patients | SVV < 10% | Bolus 3 ml/kg colloid, dobutamine | Standard of care (MAP > 65 mmHg, HR < 100 bpm, CVP = 8 to 15 mmHg, UO > 0.5 ml/kg/h) | Similar | More | Better intraoperative hemodynamic stability, lower serum lactate, less postoperative complications | Benes |
| CI > 2.5 l/min/m2 | |||||||
| Elective total hip replacement | DO2 > 600 ml/min/m2 | Bolus 250 ml colloid, dobutamine, RBC | Standard of care (MAP) | More | More | Less postoperative complications, (hypotension, cardiovascular) | Cecconi |
| ΔSV < 10%, Hb > 10 g/dl | |||||||
| Elective colorectal surgery | ΔSV < 10% | Bolus 200 ml colloid | Zero balance intraoperative fluids (MAP > 60 mmHg) | Similar | More | No difference between groups | Brandstrup |
| Major abdominal surgery (cirrhotic patients) | 2 GDT groups: | Bolus 250 ml LR followed by 3 ml/kg colloid | Same for both groups | Similar | Similar | No difference between groups | Abdullah |
| PVI < 13% | |||||||
| FTc > 350 ms | |||||||
| Major colorectal surgery | ΔSV < 10% | Bolus 200 ml colloid | Standard of care | Similar | More | More blood loss and need for transfusion in OR, longer HLOS | Challand |
| Noncardiac major surgery | FTc > 300 ms, ΔSV < 10% | Bolus 200 ml colloid | Bolus 200 ml crystalloid | Less | More | Less transfusion of FFP, better hemodynamic stability | Feldheiser |
| MAP > 70 mmHg | |||||||
| CI > 2.5 l/min/m2 | |||||||
| Elective colectomy | FTc > 400 ms | 7 ml/kg first bolus colloid, then bolus 3 ml/kg colloid | Restrictive regimen | Similar | More | No differences in outcomes | Srinivasa |
| ΔSV < 10% | (HR, MAP, UO) | ||||||
| Cytoreductive surgery (ovarian cancer) | ΔSV < 10% | Bolus 200 ml | 200 ml crystalloid | Less | More | Better hemodynamic stability, less FFP transfusion | Feldheiser |
| Major abdominal surgery | CI > 2.5 l/min/m2 | Fluids, dobutamine, vasopressors | Standard of care | Similar | Similar | Less postoperative complications, lower infection rate | Salzwedel |
| PPV < 10% | |||||||
| MAP > 65 mmHg | |||||||
| Major abdominal surgery | CO SV | Bolus 250 ml colloid | Standard of care (CVP) | Less | More | No difference in outcomes | Pearse |
Individual clinical trials and meta-analyses have shown that different fluid therapy regimens produce significantly different clinical outcomes and have resulted in considerable controversy as to the best approach. This table represents a summary of the known peer-reviewed GDT trials including their physiologic targets, fluids used, and outcomes measured.
Commonly applied crystalloid solutions: osmolality, cationic, and anionic composition
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Plasma | 285 to 295 | 7.4 | 142 | 4 | 5 | 27 | 1 | |
| 0.9% saline | 308 | 5.5 | 154 | 154 | ||||
| Lactate Ringer’s | 273 | 6.5 | 130 | 5.4 | 2.7 | 29 | 109 | |
| Plasmalyte | 294 | 7.4 | 140 | 5 | 98 | 27 |
Main current concerns regarding the use of specific crystalloids and colloids
|
|
|
|
|---|---|---|
| Normal saline | Hyperchloremic acidosis | Hyperchloremia after noncardiac surgery is independently associated with morbidity and mortality [ |
| Reduction of renal perfusion | May contribute to acute renal injury [ | |
| Starch solutions | Acute kidney injury and increased requirement of renal replacement therapy | Critically ill septic patients [ |
| Increased mortality | Critically ill septic patients [ | |
| Increased need for PRBC transfusion | Critically ill septic patients [ |
Results of clinical trials comparing fluid resuscitation with colloids and crystalloids in different populations have been conflicting. This table summarizes current concerns regarding specific crystalloids and colloids.
Figure 2Goal-directed hemodynamic algorithm to guide intraoperative volume therapy in major abdominal surgeries: (a) initial assessment and treatment and (b) further intraoperative optimization [ 58 ] (used per BioMed Central’s creative commons license). PPV, pulse pressure variation; CI, cardiac index; MAP, mean arterial pressure.
Figure 3A rational approach to intraoperative monitoring. A useful approach for assessing the needed level of hemodynamic monitoring based on the patient status, surgical risk, and clinical management requirements (what are my management needs?). NIBP, noninvasive blood pressure; ECG, electrocardiogram; A-line, arterial catheterization; NICP, noninvasive continuous pressure; CVC, central venous catheter; ECHO, transthoracic or transesophageal echocardiography; PAC, pulmonary artery catheter; ScVO2, central venous oxygen saturation; MVO2, mixed venous oxygen saturation; PCA, pulse contour analysis; BioImp, bioimpedance or bioreactance.
Principles of hemodynamic monitoring (Vincent .) [133 ]
|
|
|
|---|---|
| No hemodynamic monitoring technique can improve outcome by itself | If the data are interpreted or applied incorrectly the resultant change in management will not improve patient outcome and may be deleterious |
| Monitoring requirements may vary over time | Optimal monitoring system depend on the individual patient, the problem already present or potentially arising, and the devices and expertise available. Different monitoring techniques can sometimes be used to complement each other. |
| There are no optimal hemodynamic values or targets that are applicable to all patients | Targets and alarms should thus be individualized and reassessed regularly |
| Any variable on its own provides just one piece of a large puzzle | Variables should be combined and integrated |
| Continuous measurements of hemodynamic variables is preferable | Real time information and trends are useful on the perioperative settings |
This table highlights a fundamental truth regarding hemodynamic monitoring and patient outcomes: Hemodynamic monitoring devices do not change patient outcomes unless coupled to treatments or treatment protocols which are known to improve outcome.